nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Doxorubicin—pancreatic cancer	0.573	1	CbGbCtD
Deferoxamine—Leukopenia—Irinotecan—pancreatic cancer	0.000704	0.00165	CcSEcCtD
Deferoxamine—Paraesthesia—Sunitinib—pancreatic cancer	0.000699	0.00164	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000696	0.00163	CcSEcCtD
Deferoxamine—Infestation NOS—Docetaxel—pancreatic cancer	0.000695	0.00163	CcSEcCtD
Deferoxamine—Infestation—Docetaxel—pancreatic cancer	0.000695	0.00163	CcSEcCtD
Deferoxamine—Dyspnoea—Sunitinib—pancreatic cancer	0.000694	0.00163	CcSEcCtD
Deferoxamine—Leukopenia—Gemcitabine—pancreatic cancer	0.000685	0.00161	CcSEcCtD
Deferoxamine—Renal failure—Docetaxel—pancreatic cancer	0.000683	0.0016	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.000682	0.0016	CcSEcCtD
Deferoxamine—Leukopenia—Fluorouracil—pancreatic cancer	0.000674	0.00158	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000672	0.00158	CcSEcCtD
Deferoxamine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00067	0.00157	CcSEcCtD
Deferoxamine—Pain—Sunitinib—pancreatic cancer	0.000666	0.00156	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—pancreatic cancer	0.000659	0.00155	CcSEcCtD
Deferoxamine—Convulsion—Fluorouracil—pancreatic cancer	0.000652	0.00153	CcSEcCtD
Deferoxamine—Arthralgia—Gemcitabine—pancreatic cancer	0.000652	0.00153	CcSEcCtD
Deferoxamine—Myalgia—Gemcitabine—pancreatic cancer	0.000652	0.00153	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000647	0.00152	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000644	0.00151	CcSEcCtD
Deferoxamine—Pruritus—Tamoxifen—pancreatic cancer	0.000643	0.00151	CcSEcCtD
Deferoxamine—Oedema—Irinotecan—pancreatic cancer	0.000641	0.0015	CcSEcCtD
Deferoxamine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000641	0.0015	CcSEcCtD
Deferoxamine—Myalgia—Fluorouracil—pancreatic cancer	0.000641	0.0015	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—pancreatic cancer	0.000639	0.0015	CcSEcCtD
Deferoxamine—Infection—Irinotecan—pancreatic cancer	0.000637	0.00149	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000637	0.00149	CcSEcCtD
Deferoxamine—Pruritus—Erlotinib—pancreatic cancer	0.000636	0.00149	CcSEcCtD
Deferoxamine—Shock—Irinotecan—pancreatic cancer	0.000631	0.00148	CcSEcCtD
Deferoxamine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000629	0.00147	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000629	0.00147	CcSEcCtD
Deferoxamine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000628	0.00147	CcSEcCtD
Deferoxamine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000625	0.00146	CcSEcCtD
Deferoxamine—Oedema—Gemcitabine—pancreatic cancer	0.000625	0.00146	CcSEcCtD
Deferoxamine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000622	0.00146	CcSEcCtD
Deferoxamine—Infection—Gemcitabine—pancreatic cancer	0.000621	0.00146	CcSEcCtD
Deferoxamine—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000616	0.00144	CcSEcCtD
Deferoxamine—Abdominal pain—Sunitinib—pancreatic cancer	0.000616	0.00144	CcSEcCtD
Deferoxamine—Body temperature increased—Sunitinib—pancreatic cancer	0.000616	0.00144	CcSEcCtD
Deferoxamine—Diarrhoea—Erlotinib—pancreatic cancer	0.000616	0.00144	CcSEcCtD
Deferoxamine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000614	0.00144	CcSEcCtD
Deferoxamine—Oedema—Fluorouracil—pancreatic cancer	0.000614	0.00144	CcSEcCtD
Deferoxamine—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000613	0.00144	CcSEcCtD
Deferoxamine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000613	0.00144	CcSEcCtD
Deferoxamine—Urethral disorder—Docetaxel—pancreatic cancer	0.000612	0.00143	CcSEcCtD
Deferoxamine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000612	0.00143	CcSEcCtD
Deferoxamine—Infection—Fluorouracil—pancreatic cancer	0.00061	0.00143	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—pancreatic cancer	0.00061	0.00143	CcSEcCtD
Deferoxamine—Skin disorder—Gemcitabine—pancreatic cancer	0.000607	0.00142	CcSEcCtD
Deferoxamine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000603	0.00141	CcSEcCtD
Deferoxamine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000602	0.00141	CcSEcCtD
Deferoxamine—Visual impairment—Docetaxel—pancreatic cancer	0.000601	0.00141	CcSEcCtD
Deferoxamine—Dizziness—Tamoxifen—pancreatic cancer	0.000601	0.00141	CcSEcCtD
Deferoxamine—Tachycardia—Fluorouracil—pancreatic cancer	0.0006	0.00141	CcSEcCtD
Deferoxamine—Hypotension—Irinotecan—pancreatic cancer	0.000599	0.00141	CcSEcCtD
Deferoxamine—Dizziness—Erlotinib—pancreatic cancer	0.000595	0.00139	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—pancreatic cancer	0.000592	0.00139	CcSEcCtD
Deferoxamine—Hypotension—Gemcitabine—pancreatic cancer	0.000584	0.00137	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—pancreatic cancer	0.000583	0.00137	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000582	0.00136	CcSEcCtD
Deferoxamine—Vomiting—Tamoxifen—pancreatic cancer	0.000578	0.00136	CcSEcCtD
Deferoxamine—Paraesthesia—Irinotecan—pancreatic cancer	0.000576	0.00135	CcSEcCtD
Deferoxamine—Hypotension—Fluorouracil—pancreatic cancer	0.000574	0.00135	CcSEcCtD
Deferoxamine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000574	0.00134	CcSEcCtD
Deferoxamine—Vomiting—Erlotinib—pancreatic cancer	0.000572	0.00134	CcSEcCtD
Deferoxamine—Dyspnoea—Irinotecan—pancreatic cancer	0.000572	0.00134	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—pancreatic cancer	0.00057	0.00134	CcSEcCtD
Deferoxamine—Headache—Tamoxifen—pancreatic cancer	0.00057	0.00134	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000569	0.00133	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—pancreatic cancer	0.000566	0.00133	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—pancreatic cancer	0.000564	0.00132	CcSEcCtD
Deferoxamine—Headache—Erlotinib—pancreatic cancer	0.000564	0.00132	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000563	0.00132	CcSEcCtD
Deferoxamine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000561	0.00132	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00056	0.00131	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—pancreatic cancer	0.000558	0.00131	CcSEcCtD
Deferoxamine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000557	0.00131	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000554	0.0013	CcSEcCtD
Deferoxamine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000552	0.00129	CcSEcCtD
Deferoxamine—Pruritus—Sunitinib—pancreatic cancer	0.000551	0.00129	CcSEcCtD
Deferoxamine—Pain—Irinotecan—pancreatic cancer	0.000549	0.00129	CcSEcCtD
Deferoxamine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000548	0.00128	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—pancreatic cancer	0.000543	0.00127	CcSEcCtD
Deferoxamine—Nausea—Tamoxifen—pancreatic cancer	0.00054	0.00127	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000539	0.00126	CcSEcCtD
Deferoxamine—Pain—Gemcitabine—pancreatic cancer	0.000534	0.00125	CcSEcCtD
Deferoxamine—Nausea—Erlotinib—pancreatic cancer	0.000534	0.00125	CcSEcCtD
Deferoxamine—Diarrhoea—Sunitinib—pancreatic cancer	0.000533	0.00125	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00053	0.00124	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000528	0.00124	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—pancreatic cancer	0.000526	0.00123	CcSEcCtD
Deferoxamine—Pain—Fluorouracil—pancreatic cancer	0.000525	0.00123	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000525	0.00123	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—pancreatic cancer	0.000522	0.00122	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—pancreatic cancer	0.000521	0.00122	CcSEcCtD
Deferoxamine—Dizziness—Sunitinib—pancreatic cancer	0.000515	0.00121	CcSEcCtD
Deferoxamine—Abdominal pain—Irinotecan—pancreatic cancer	0.000507	0.00119	CcSEcCtD
Deferoxamine—Body temperature increased—Irinotecan—pancreatic cancer	0.000507	0.00119	CcSEcCtD
Deferoxamine—Vomiting—Sunitinib—pancreatic cancer	0.000495	0.00116	CcSEcCtD
Deferoxamine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000494	0.00116	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—pancreatic cancer	0.000492	0.00115	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—pancreatic cancer	0.000488	0.00114	CcSEcCtD
Deferoxamine—Headache—Sunitinib—pancreatic cancer	0.000488	0.00114	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—pancreatic cancer	0.000487	0.00114	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—pancreatic cancer	0.000486	0.00114	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000486	0.00114	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—pancreatic cancer	0.000482	0.00113	CcSEcCtD
Deferoxamine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000473	0.00111	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—pancreatic cancer	0.000471	0.0011	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—pancreatic cancer	0.000469	0.0011	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—pancreatic cancer	0.000469	0.0011	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—pancreatic cancer	0.000463	0.00108	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—pancreatic cancer	0.000463	0.00108	CcSEcCtD
Deferoxamine—Nausea—Sunitinib—pancreatic cancer	0.000463	0.00108	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—pancreatic cancer	0.000461	0.00108	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.00046	0.00108	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000459	0.00108	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—pancreatic cancer	0.000455	0.00107	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000453	0.00106	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—pancreatic cancer	0.000443	0.00104	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000443	0.00104	CcSEcCtD
Deferoxamine—Pruritus—Gemcitabine—pancreatic cancer	0.000442	0.00104	CcSEcCtD
Deferoxamine—Infection—Docetaxel—pancreatic cancer	0.000441	0.00103	CcSEcCtD
Deferoxamine—Diarrhoea—Irinotecan—pancreatic cancer	0.000439	0.00103	CcSEcCtD
Deferoxamine—Shock—Docetaxel—pancreatic cancer	0.000436	0.00102	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000435	0.00102	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—pancreatic cancer	0.000435	0.00102	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000434	0.00102	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—pancreatic cancer	0.000434	0.00102	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—pancreatic cancer	0.000434	0.00102	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—pancreatic cancer	0.000433	0.00101	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—pancreatic cancer	0.000431	0.00101	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—pancreatic cancer	0.000429	0.001	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000428	0.001	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—pancreatic cancer	0.000427	0.001	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000425	0.000997	CcSEcCtD
Deferoxamine—Dizziness—Irinotecan—pancreatic cancer	0.000424	0.000994	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—pancreatic cancer	0.00042	0.000985	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000416	0.000975	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—pancreatic cancer	0.000414	0.000971	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000414	0.00097	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—pancreatic cancer	0.000413	0.000967	CcSEcCtD
Deferoxamine—Vomiting—Irinotecan—pancreatic cancer	0.000408	0.000956	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—pancreatic cancer	0.000406	0.000952	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—pancreatic cancer	0.000406	0.000951	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000404	0.000947	CcSEcCtD
Deferoxamine—Headache—Irinotecan—pancreatic cancer	0.000402	0.000942	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—pancreatic cancer	0.000398	0.000933	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—pancreatic cancer	0.000397	0.000931	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—pancreatic cancer	0.000397	0.00093	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—pancreatic cancer	0.000395	0.000927	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—pancreatic cancer	0.000393	0.000922	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—pancreatic cancer	0.000393	0.00092	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—pancreatic cancer	0.000391	0.000918	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—pancreatic cancer	0.000391	0.000916	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—pancreatic cancer	0.000385	0.000902	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000385	0.000902	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000383	0.000897	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000383	0.000897	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—pancreatic cancer	0.000382	0.000895	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—pancreatic cancer	0.000382	0.000895	CcSEcCtD
Deferoxamine—Nausea—Irinotecan—pancreatic cancer	0.000381	0.000893	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—pancreatic cancer	0.00038	0.000891	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000379	0.000889	CcSEcCtD
Deferoxamine—Pain—Docetaxel—pancreatic cancer	0.000379	0.000889	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—pancreatic cancer	0.000376	0.000882	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—pancreatic cancer	0.000375	0.00088	CcSEcCtD
Deferoxamine—Nausea—Gemcitabine—pancreatic cancer	0.000371	0.00087	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—pancreatic cancer	0.000366	0.000859	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—pancreatic cancer	0.000365	0.000855	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—pancreatic cancer	0.000364	0.000853	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—pancreatic cancer	0.000363	0.000851	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000363	0.00085	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—pancreatic cancer	0.000353	0.000828	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—pancreatic cancer	0.000352	0.000826	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—pancreatic cancer	0.000352	0.000825	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000351	0.000823	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—pancreatic cancer	0.000351	0.000822	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—pancreatic cancer	0.000351	0.000822	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000348	0.000816	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—pancreatic cancer	0.000345	0.00081	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—pancreatic cancer	0.000339	0.000795	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—pancreatic cancer	0.000328	0.000769	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000327	0.000766	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000326	0.000764	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—pancreatic cancer	0.00032	0.000749	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—pancreatic cancer	0.000318	0.000744	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—pancreatic cancer	0.000314	0.000735	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—pancreatic cancer	0.000312	0.000731	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—pancreatic cancer	0.000312	0.000731	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00031	0.000726	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—pancreatic cancer	0.000304	0.000712	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—pancreatic cancer	0.000303	0.000711	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000299	0.000701	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—pancreatic cancer	0.000299	0.000701	CcSEcCtD
Deferoxamine—Infection—Epirubicin—pancreatic cancer	0.000297	0.000697	CcSEcCtD
Deferoxamine—Shock—Epirubicin—pancreatic cancer	0.000294	0.00069	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—pancreatic cancer	0.000294	0.000689	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000293	0.000688	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—pancreatic cancer	0.000293	0.000687	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000293	0.000686	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—pancreatic cancer	0.000292	0.000684	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—pancreatic cancer	0.000291	0.000681	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—pancreatic cancer	0.000289	0.000677	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—pancreatic cancer	0.000289	0.000677	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000287	0.000672	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—pancreatic cancer	0.000282	0.000661	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—pancreatic cancer	0.000279	0.000655	CcSEcCtD
Deferoxamine—Headache—Docetaxel—pancreatic cancer	0.000278	0.000651	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000277	0.000649	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—pancreatic cancer	0.000277	0.000649	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—pancreatic cancer	0.000275	0.000644	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000273	0.000639	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—pancreatic cancer	0.000272	0.000638	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000271	0.000636	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000271	0.000635	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—pancreatic cancer	0.00027	0.000633	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—pancreatic cancer	0.000269	0.00063	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—pancreatic cancer	0.000269	0.00063	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—pancreatic cancer	0.000267	0.000625	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—pancreatic cancer	0.000263	0.000617	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—pancreatic cancer	0.000259	0.000606	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000258	0.000605	CcSEcCtD
Deferoxamine—Pain—Epirubicin—pancreatic cancer	0.000256	0.0006	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000252	0.000591	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000249	0.000583	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000247	0.000578	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000245	0.000573	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000239	0.00056	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—pancreatic cancer	0.000238	0.000557	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—pancreatic cancer	0.000237	0.000555	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—pancreatic cancer	0.000236	0.000554	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—pancreatic cancer	0.000236	0.000554	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000226	0.00053	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—pancreatic cancer	0.00022	0.000517	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—pancreatic cancer	0.00022	0.000515	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000219	0.000513	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000219	0.000513	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—pancreatic cancer	0.000212	0.000496	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—pancreatic cancer	0.000205	0.00048	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000204	0.000478	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—pancreatic cancer	0.000198	0.000464	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—pancreatic cancer	0.000196	0.000459	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—pancreatic cancer	0.00019	0.000446	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000189	0.000444	CcSEcCtD
Deferoxamine—Headache—Epirubicin—pancreatic cancer	0.000187	0.000439	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—pancreatic cancer	0.000183	0.000429	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—pancreatic cancer	0.000178	0.000416	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—pancreatic cancer	0.000176	0.000412	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—pancreatic cancer	0.000173	0.000406	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—pancreatic cancer	0.000164	0.000385	CcSEcCtD
